The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age \> 18 years, regardless of gender.
2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
4. Availability of complete clinicopathological and follow-up data.
5. Signed and dated informed consent form.
Exclusion Criteria:
1. Patients who have previously received anti-tumor therapy.
2. Patients with a history of other malignancies.
3. Incomplete clinical information or imaging data.
4. Concurrent other malignant tumors.
5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
6. Poor compliance.
Primary outcome measure(s)
Standardized uptake value (SUV) — Baseline and 7-10 days after treatment SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
Trial sites (1)
Facility
City
Region
Status
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.